SEARCH

SEARCH BY CITATION

References

  • 1
    Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346: 75263.
  • 2
    Arnout J, Vermylen J. Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease. J Thromb Haemost 2003; 1: 93142.
  • 3
    Rosove MH, Petronella MC, Brewer PMC. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992; 117: 3038.
  • 4
    Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV. The management of thrombosis in the antiphospholipid syndrome. N Engl J Med 1995; 332: 9937.
  • 5
    Ruiz-Irastorza G, Khamashta MA, Hunt BJ, Escudero A, Cuadrado MJ, Hughes GRV. Bleeding and recurrent thrombosis in definite antiphospholipid syndrome. Arch Intern Med 2002; 162: 11649.
  • 6
    Al-Sayegh FA, Ensworth S, Huang S, Stein HB, Klinkoff AV. Hemorrhagic complications of long-term anticoagulant therapy in seven patients with systemic lupus erythematosus and antiphospholipid syndrome. J Rheumatol 1997; 24: 17168.
  • 7
    Odén A, Fahlén M. Oral anticoagulation and risk of death: a medical record linkage study. Br Med J 2002; 325: 10735.
  • 8
    Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, Laskin C, Fortin P, Anderson D, Kearon C, Clarke A, Geerts W, Forgie M, Green D, Costantini L, Yacura W, Wilson S, Gent M, Kovacs MJ. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 11338.
  • 9
    GISSI Prevenzione Investigators. n-3 PUFA and vitamin E in 11,324 post-MI patients: Results of the GISSI Prevenzione trial. Lancet 1999; 354: 44755.
  • 10
    Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, et al. for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 175562.
  • 11
    Finazzi G, Brancaccio V, Moia M, Ciavarella N, Mazzucconi MG, Schinco P, Ruggeri M, Pogliani EM, Gamba G, Rossi E, Baudo F, Manotti C, D'Angelo A, Palareti G, De Stefano V, Berrettini M, Barbui T. Natural history and risk factor for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian registry. Am J Med 1996; 100: 5306.
  • 12
    Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost 1995; 74: 118590.
  • 13
    Harris EN, Gharavi AE, Patel SP, Hughes GRV. Evaluation of the anticardiolipin antibody test: report of a standardization workshop, held April 4th, 1986. Clin Exp Immunol 1987; 68: 215222.
  • 14
    The APASS Investigators. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004; 291: 57684.